StockData
Processa Pharmaceuticals, Inc. logo

Processa Pharmaceuticals, Inc. (PCSA) stock

PCSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$1.86+0.02 (+1.09%)

Close on Nov 13, 2026Market cap $5.20MP/E –Yield –

Earnings

Processa Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Processa Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2022ended Dec 31, 2022Mar 31, 2023before the open–––Release
Q3 FY2022ended Sep 30, 2022Nov 8, 2022after the close–––Release
Q2 FY2022ended Jun 30, 2022Aug 12, 2022during market hours–––Release
Q2 FY2021ended Jun 30, 2021Aug 13, 2021before the open–––Filing
Q1 FY2021ended Mar 31, 2021May 13, 2021after the close–––Filing
Q4 FY2020ended Dec 31, 2020Mar 25, 2021after the close–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Processa Pharmaceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Processa Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Processa Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. In July, Processa acquired Vidya Therapeutics and completed a concurrent private placement financing of approximately $200 million supported by leading institutional
    News
  2. Processa Pharmaceuticals Announces Key Leadership Appointments
    News
  3. Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics
    News
  4. We are a clinical stage biotechnology company with experienced immunology drug developers seeking to improve and expand treatment options for patients suffering from
    News
  5. You should carefully consider the risks described below, as well as general economic and business risks and the other
    News
  6. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
    News
  7. PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO
    Update
  8. 8-K exhibit EX-99.2
    Update
  9. Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
    Update
  10. Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
    Update
  11. Pharmaceuticals Provides Portfolio and Business Update
    Update
  12. Pharmaceuticals Announces Pricing of $7 Million Public Offering
    Update
  13. Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
    Update
  14. 8-K exhibit EX-99.1
    Update
  15. Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The- Market Under Nasdaq Rules
    Update

See a number that looks wrong?